Cargando…
Adjuvant Intravitreal Bevacizumab for Retinal Neovascularization in Eales’ Disease Associated With Latent Mycobacterium Tuberculosis
We report a case of bilateral Eales’ disease managed with intravitreal bevacizumab. A 32-year-old woman with a history of bacillus Calmette-Guerin vaccine, administered when she was 10 years old, presented with a five-day history of a scotoma in the temporal field of her right eye. A dilated fundus...
Autores principales: | Gonzalez Martinez, Orlando G, Villegas, Victor M, Oliver, Armando L, Santos, Carmen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371457/ https://www.ncbi.nlm.nih.gov/pubmed/37503481 http://dx.doi.org/10.7759/cureus.41003 |
Ejemplares similares
-
Intravitreal Bevacizumab for Choroidal Neovascular Membrane in Macular Telangiectasia Type 2
por: Gonzalez Martinez, Orlando G, et al.
Publicado: (2023) -
Role of Intravitreal Bevacizumab in Management of Eale’s Disease
por: Mehboob, Mohammad Asim, et al.
Publicado: (2018) -
Intravitreal bevacizumab as an adjunct to vitrectomy in advanced Eales’ disease
por: Thakar, Meenakshi, et al.
Publicado: (2011) -
Successful Use of Intravitreal Bevacizumab and Methotrexate in a Case of Neovascularization of the Iris and Pseudohypopyon Secondary to Recurrent Diffuse Large B-Cell Lymphoma
por: Ahmed, Harris, et al.
Publicado: (2022) -
Double Trouble: Eales Disease in a Background of Paradoxical Embolism
por: Horvath, David, et al.
Publicado: (2023)